IGF2BP3 and neoplasm: No statistically significant differences were detected with regards to age, gender, or final pathologic tumor size between the RET/PTC and THADA/IGF2BP3 fusion cohorts (p = 0.064, p = 0.154, and p = 0.104, respectively).